Category: NAFLD Prevalence

All Podcast Categories
S4-E48.1 - Reviewing TLM 2023 Part One: A Discussion With Zobair Younossi

S4-E48.1 – Reviewing TLM 2023 Part One: A Discussion With Zobair Younossi

Dr. Zobair Younossi joins Roger Green to kick off our review coverage of TLM 2023. Dr. Younossi discusses the studies he presented at the meeting and discusses other work related to patient quality-of-life, economics of screening and treatment, and how stigma affects both patients and providers.

S4-41.6 - From the Vault: Highlights from Paris NASH 2021

S4-41.6 – From the Vault: Highlights from Paris NASH 2021

In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!

S4-41.3 - Laurent Castera on the FDA's NIT Workshop

S4-41.3 – Laurent Castera on the FDA’s NIT Workshop

In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. Laurent focuses on why this workshop is important within its context of being hosted by the FDA and what that means for researchers and stakeholders across the globe. He also dives into the complexities of hepatocellular ballooning and its potential impact on patients receiving NASH pharmacotherapy.

S4-41.1 - Naim Alkhouri on an NIT-based alternative path to conditional approval

S4-41.1 – Naim Alkhouri on an NIT-based alternative path to conditional approval

In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. Naim expands on ideas around an NIT-based alternative path to conditional approval as well as provides a general survey of how the workshop played out as he served as an expert panelist in Tuesday’s penultimate session.

S4-40.5 - Paris NASH Review: More Topics and Final Thoughts

S4-40.5 – Paris NASH Review: More Topics and Final Thoughts

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating final conversation which raises new and interesting topics covered at the event.

S4-40.4 - Challenges in Treating and Assessing Adequately

S4-40.4 – Challenges in Treating and Assessing Adequately

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a conversation around the complex challenges in adequately assessing and treating patients.

S4-40.3 - Which test is best for which patients?

S4-40.3 – Which test is best for which patients?

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. In this conversation, presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green to ask and answer questions surrounding the task of testing patients for optimized results under different scenarios.

S4-40.2 - Deeper Dive into the Landscape of NITs

S4-40.2 – Deeper Dive into the Landscape of NITs

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating conversation that dives deeper into emerging questions surrounding the use of NITs in a landscape which features drug approval.